Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Sees Large Decrease in Short Interest

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) was the target of a significant decrease in short interest in January. As of January 15th, there was short interest totaling 28,466 shares, a decrease of 19.7% from the December 31st total of 35,432 shares. Approximately 2.2% of the shares of the stock are sold short. Based on an average daily trading volume, of 17,316 shares, the days-to-cover ratio is presently 1.6 days. Based on an average daily trading volume, of 17,316 shares, the days-to-cover ratio is presently 1.6 days. Approximately 2.2% of the shares of the stock are sold short.

Institutional Trading of Sonoma Pharmaceuticals

A hedge fund recently bought a new stake in Sonoma Pharmaceuticals stock. Heron Bay Capital Management bought a new stake in shares of Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 33,782 shares of the company’s stock, valued at approximately $96,000. Heron Bay Capital Management owned approximately 2.06% of Sonoma Pharmaceuticals at the end of the most recent reporting period. 1.95% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Sonoma Pharmaceuticals in a research report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has an average rating of “Sell”.

Sonoma Pharmaceuticals Stock Up 0.9%

Shares of SNOA stock traded up $0.03 during mid-day trading on Tuesday, reaching $3.24. 17,389 shares of the stock traded hands, compared to its average volume of 13,613. The company has a market cap of $5.51 million, a price-to-earnings ratio of -1.48 and a beta of 1.65. The stock’s fifty day simple moving average is $3.48 and its two-hundred day simple moving average is $3.79. Sonoma Pharmaceuticals has a 1-year low of $1.75 and a 1-year high of $6.92.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.18. Sonoma Pharmaceuticals had a negative net margin of 20.57% and a negative return on equity of 45.46%. On average, equities research analysts anticipate that Sonoma Pharmaceuticals will post -0.67 EPS for the current fiscal year.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc is a specialty dermatology company focused on developing and commercializing topical prescription and over-the-counter products for inflammatory and infectious skin conditions. Publicly traded on Nasdaq under the symbol SNOA, the company concentrates its efforts on areas such as acne, rosacea, dermatitis and wound care, aiming to provide physicians and patients with innovative treatment options.

At the heart of Sonoma’s technology platform lies its proprietary Triphasic drug delivery system, which enables the timed release of active ingredients through three distinct gel phases.